Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supplemental parenteral nutrition in definitive radiotherapy for inoperable head and neck cancer
2014-003833-24Phase 3Terminated
- Sponsor
- AGMT
- Start
- Jun 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of cetuximab and cisplatin in head and neck cancer (HNC) and oropharyngeal squamous cell carcinoma (OPSCC) (2 arms), sponsored by AGMT. Primary endpoint: Critical weight loss at end of radiotherapy. Started Jun 2016; status: terminated.
02
Drugs
cetuximabcisplatin
03
Conditions
head and neck cancer (HNC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on 2014-003833-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003833-24.